SCHEMBL13675006

SCHEMBL13675006

CN(c1cccc2cc(-c3ncc(CCC(=O)NS)s3)[nH]c12)S(=O)(=O)c1cccs1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.34
LMNA P02545 3/20 0.34
HTT P42858 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ALDH1A1 P00352 4/20 0.34
GCK P35557 3/20 0.34
POLB P06746 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
TSHR P16473 5/20 0.33
L3MBTL1 Q9Y468 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPK1 P28482 1/20 0.33
MEN1 O00255 1/20 0.33
THRB P10828 1/20 0.32
USP2 O75604 1/20 0.32
PKM P14618 1/20 0.32
ALOX15 P16050 1/20 0.32
ALOX12 P18054 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1653836 0.92 MAPT (0.34) MAPTLMNAHTTNPSR1ALDH1A1
SCHEMBL1653299 0.91 GCK (0.36) MAPTLMNAHTTNPSR1ALDH1A1
SCHEMBL1653116 0.90 GCK (0.39) MAPTLMNAHTTNPSR1ALDH1A1
SCHEMBL1653284 0.90 GCK (0.34) MAPTLMNAHTTNPSR1ALDH1A1
SCHEMBL1653485 0.87 ALDH1A1 (0.39) MAPTLMNAHTTNPSR1ALDH1A1
SCHEMBL1653422 0.86 ALDH1A1 (0.35) MAPTLMNAHTTNPSR1ALDH1A1
SCHEMBL1653389 0.85 ALDH1A1 (0.34) MAPTLMNAHTTNPSR1ALDH1A1
SCHEMBL1653985 0.85 ALDH1A1 (0.36) MAPTLMNAHTTNPSR1ALDH1A1
SCHEMBL13675209 0.84 ALDH1A1 (0.35) MAPTLMNAHTTNPSR1ALDH1A1
SCHEMBL1654862 0.84 LMNA (0.38) LMNAHTTALDH1A1GCKNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247746-A1 Fused heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247746-A1 Fused heterocyclic compound GCKR, GCK, GPR119 MAPT 4377/4885LMNA 4417/4885HTT 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.